Tapestry Pharmaceuticals says it will lay off 14 workers, 28 percent of its staff, as it concentrates all of its efforts on advancing TPI 287 for prostate and pancreatic cancer. Boulder, CO-based Tapestry says it can save $11 million in the strategic shift. Release